CY1115227T1 - Νεοι καταστολεις φωσφοδιεστερασης (phosphodiesterase) - Google Patents

Νεοι καταστολεις φωσφοδιεστερασης (phosphodiesterase)

Info

Publication number
CY1115227T1
CY1115227T1 CY20141100437T CY141100437T CY1115227T1 CY 1115227 T1 CY1115227 T1 CY 1115227T1 CY 20141100437 T CY20141100437 T CY 20141100437T CY 141100437 T CY141100437 T CY 141100437T CY 1115227 T1 CY1115227 T1 CY 1115227T1
Authority
CY
Cyprus
Prior art keywords
representatives
compounds
new phosphodiesterase
phosphodiesterase
new
Prior art date
Application number
CY20141100437T
Other languages
English (en)
Inventor
Jakob Felding
Simon Feldbaek Nielsen
Jens Christian Hojland Larsen
Bollu Ravindra Babu
Original Assignee
Leo Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma A/S filed Critical Leo Pharma A/S
Publication of CY1115227T1 publication Critical patent/CY1115227T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Abstract

Η παρούσα εφεύρεση σχετίζεται με μία ένωση σύμφωνα με τον τύπο I, όπου τα Χ, A, G, Ε, R1, R2, R3 είναι όπως φαίνεται στην παρούσα και φαρμακευτικά αποδεκτά άλατα, ένυδρα, Ν-οξείδια ή διαλυτώματα αυτών. Η εφεύρεση σχετίζεται περαιτέρω με τις εν λόγω ενώσεις, με μεθόδους θεραπείας ασθενειών, π.χ. δερματικών ασθενειών, με τις εν λόγω ενώσεις, και την χρήση των εν λόγω ενώσεων στην κατασκευή φαρμάκων.
CY20141100437T 2007-02-28 2014-06-17 Νεοι καταστολεις φωσφοδιεστερασης (phosphodiesterase) CY1115227T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90384907P 2007-02-28 2007-02-28
US94684907P 2007-06-28 2007-06-28
EP08706922.5A EP2114951B9 (en) 2007-02-28 2008-02-26 Novel phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
CY1115227T1 true CY1115227T1 (el) 2017-01-04

Family

ID=39415336

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100437T CY1115227T1 (el) 2007-02-28 2014-06-17 Νεοι καταστολεις φωσφοδιεστερασης (phosphodiesterase)

Country Status (22)

Country Link
US (1) US8338431B2 (el)
EP (1) EP2114951B9 (el)
JP (1) JP5501770B2 (el)
KR (1) KR101571654B1 (el)
AU (1) AU2008221121B2 (el)
BR (1) BRPI0807749B8 (el)
CA (1) CA2676933C (el)
CY (1) CY1115227T1 (el)
DK (1) DK2114951T3 (el)
ES (1) ES2478670T3 (el)
HK (1) HK1138262A1 (el)
HR (1) HRP20140585T1 (el)
IL (1) IL200153A (el)
MX (1) MX2009009238A (el)
MY (1) MY150075A (el)
NZ (1) NZ578804A (el)
PL (1) PL2114951T3 (el)
PT (1) PT2114951E (el)
RS (1) RS53407B (el)
RU (1) RU2495043C2 (el)
SI (1) SI2114951T1 (el)
WO (1) WO2008104175A2 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2560677C2 (ru) 2009-12-22 2015-08-20 Лео Фарма А/С Кожная композиция, включающая аналог витамина d и смесь растворителя и поверхностно-активных веществ
MX2012007234A (es) 2009-12-22 2012-07-30 Leo Pharma As Nanocristales de monohidrato de calciprotiol.
ES2452872T3 (es) 2009-12-22 2014-04-03 Leo Pharma A/S Composición farmacéutica que comprende una mezcla solvente y un derivado o análogo de vitamina D
PT2585469T (pt) 2010-06-24 2016-08-29 Leo Pharma As Compostos heterocíclicos de benzodioxolo ou benzodioxepina como inibidores da fosfodiesterase
WO2013122855A1 (en) * 2012-02-14 2013-08-22 University Of Rochester Methods of increasing lymphatic transport
RU2637945C2 (ru) * 2012-06-04 2017-12-08 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные 1-фенил-2-пиридинил-алкиловых спиртов в качестве ингибиторов фосфодиэстеразы
RU2663448C2 (ru) * 2012-11-30 2018-08-06 Лео Фарма А/С Способ ингибирования экспрессии ил-22 активированными т-клетками
JP6785666B2 (ja) * 2014-06-23 2020-11-18 レオ ファーマ アクティーゼルスカブ １，３−ベンゾジオキソール複素環化合物の調製方法
EP3310777B1 (en) 2015-06-19 2019-10-09 Bristol-Myers Squibb Company Diamide macrocycles as factor xia inhibitors
CA3007432A1 (en) * 2015-12-18 2017-06-22 Leo Pharma A/S Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
US10793580B2 (en) 2016-12-12 2020-10-06 Leo Pharma A/S Substituted pyrazoloazepin-8-ones and their use as phosphodiesterase inhibitors
EP3551633B1 (en) * 2016-12-12 2021-03-31 Leo Pharma A/S Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors
EP3551632A1 (en) * 2016-12-12 2019-10-16 Leo Pharma A/S Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors
AU2018286964B2 (en) * 2017-06-20 2022-04-14 UNION therapeutics A/S Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
TW201919682A (zh) 2017-08-08 2019-06-01 西班牙商阿爾米雷爾有限公司 活化Ｎｒｆ２路徑的新穎化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9507297D0 (en) 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
JP4172817B2 (ja) * 1995-05-19 2008-10-29 協和醗酵工業株式会社 含酸素複素環化合物
US6514996B2 (en) 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
NZ332340A (en) 1996-05-20 2000-04-28 Darwin Discovery Ltd 4-(aryl or heteroaryl) substituted benzofurancarboxamide derivatives and medicaments
ATE272062T1 (de) * 1996-08-28 2004-08-15 Procter & Gamble Spirocyclisch metalloprotease inhibitoren
EP0943613A4 (en) * 1996-11-19 2002-07-10 Kyowa Hakko Kogyo Kk HETEROCYCLIC COMPOUNDS CONTAINING OXYGEN
JP4219554B2 (ja) * 1997-10-01 2009-02-04 協和発酵キリン株式会社 ベンゾフラン誘導体
DE19907038C2 (de) 1999-02-19 2003-04-10 Schott Glas Transluzente oder opake Glaskeramik mit Hochquarz-Mischkristallen als vorherrschender Kristallphase und deren Verwendung

Also Published As

Publication number Publication date
CA2676933C (en) 2015-09-29
US8338431B2 (en) 2012-12-25
MY150075A (en) 2013-11-29
HRP20140585T1 (hr) 2014-09-12
BRPI0807749B8 (pt) 2022-09-06
EP2114951B1 (en) 2014-04-09
US20100099688A1 (en) 2010-04-22
KR20090126252A (ko) 2009-12-08
JP2010519332A (ja) 2010-06-03
PT2114951E (pt) 2014-07-17
RU2009135810A (ru) 2011-04-10
WO2008104175A2 (en) 2008-09-04
WO2008104175A3 (en) 2009-01-29
IL200153A0 (en) 2010-04-15
CA2676933A1 (en) 2008-09-04
MX2009009238A (es) 2009-09-08
RU2495043C2 (ru) 2013-10-10
DK2114951T3 (da) 2014-06-23
NZ578804A (en) 2012-04-27
IL200153A (en) 2016-11-30
BRPI0807749B1 (pt) 2021-01-05
EP2114951B9 (en) 2015-09-02
RS53407B (en) 2014-10-31
KR101571654B1 (ko) 2015-11-25
EP2114951A2 (en) 2009-11-11
JP5501770B2 (ja) 2014-05-28
AU2008221121B2 (en) 2013-10-03
BRPI0807749A2 (pt) 2014-06-17
AU2008221121A1 (en) 2008-09-04
SI2114951T1 (sl) 2014-08-29
HK1138262A1 (en) 2010-08-20
ES2478670T3 (es) 2014-07-22
PL2114951T3 (pl) 2014-10-31

Similar Documents

Publication Publication Date Title
CY1115227T1 (el) Νεοι καταστολεις φωσφοδιεστερασης (phosphodiesterase)
CY1120073T1 (el) Παραγωγα πυραζολο-αμινοπυριμιδινης ως ρυθμιστες της lrrk2
CY1123991T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1122863T1 (el) Φαρμακευτικη συνθεση που περιεχει γλυκοπυρρολικο και εναν αγωνιστη βητα2 αδρενοϋποδοχεα
CY1118993T1 (el) Υποκατεστημενες ενωσεις τετραϋδροϊσοκινολινης ως αναστολεις τελεστη xiα
CY1118771T1 (el) Μακροκυκλικα παραγωγα για την αγωγη υπερπλαστικων παθησεων
CY1113209T1 (el) Νεα παραγωγα πυρρολο [3,2-d] πυριμιδιν-4-ονης και η χρηση τους στη θεραπεια
CY1116103T1 (el) Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης
CY1117719T1 (el) Παραγωγα αμινοπυριμιδινης ως διαμορφωτες της lrrk2
CY1118610T1 (el) Αναστολεις κινασεων και η χρηση τους στη θεραπευτικη αγωγη του καρκινου
CY1117193T1 (el) Φαρμακευτικη συνθεση για θεραπεια ή αποτροπη γλαυκωματος
CY1117197T1 (el) Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ
CY1122349T1 (el) Παραγωγα 1-benzyλ-3-υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των mcp-1, cxcr1 και ρ40
CY1110247T1 (el) Παραγωγα βενζοκιναζολινης και η χρηση τους στην θεραπεια των διαταραχων των οστων
CY1118340T1 (el) Αναστολεις κινασης
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
CY1118135T1 (el) Παραγωγα 2-(φαινυλο ή πυριδ-3-υλο) αμινοπυριμιδινης ως ρυθμιστες κινασης lrrk2 για τη θεραπευτικη αντιμετωπιση της νοσου του parkinson
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
CY1112495T1 (el) Κυτταροτοξικοι παραγοντες που περιλαμβανουν νεα παραγωγα τομαϋμυκινης
CY1109644T1 (el) 2,4-διαμινο-πυριμιδινες ως αναστολεις audora
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
CY1112311T1 (el) Ενωσεις πυραζολινης ως ανταγωνιστες υποδοχεα αλατοκορτικοειδους
CY1114277T1 (el) ΕΝΩΣΕΙΣ ΙΜΙΔΑΖΟ[1,2-a]ΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΥΠΟΔΟΧΕΑ ΚΙΝΑΣΗΣ ΤΥΡΟΣΙΝΗΣ
CY1105441T1 (el) Ετepοκυκλικοι σουλφοναμιδικοι αναστολεις της παραγωγης βητα αμυλοειδους
CY1110962T1 (el) Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων